Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-γδT Cell Injection for Relapsed/Refractory Leukemia
NCT07120607Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides
01
Overview
Phase 1, open-label, single-arm trial of QHRD106 in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL) and acute myeloid leukemia (AML), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Incidence of Adverse Events at 12 months and Incidence of Dose-Limiting Toxicities at 28 days. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QHRD106
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07120607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120607.